-
Eureka Biotech Partners with Ucello for Universal CAR-T Cell Therapy Development
•
Shenzhen Eureka Biotechnology Co., Limited, a China-based biotech firm, has entered into a partnership with compatriot Chengdu Ucello Biotechnology Co., Ltd. The collaboration aims to develop universal cell therapies by integrating Eureka’s CellSep series cell preparation system and its world-class EuLV-based lentivirus production system based on stable cell lines into…
-
Merck Sharp & Dohme Partners with Sinopharm for Molnupiravir in China
•
US-based Merck Sharp & Dohme (MSD, NYSE: MRK) has entered into a cooperation framework agreement with China National Pharmaceutical Group Co., Ltd (Sinopharm), granting Sinopharm agency and exclusive importing rights to its oral small molecule COVID-19 drug, molnupiravir, in China. The collaboration will also explore the feasibility of technology transfer…
-
NMPA Releases 59th Batch of Reference Drugs for Generic Quality Evaluation
•
The National Medical Products Administration (NMPA) has released the 59th batch of reference drugs for generic quality consistency evaluation (GQCE) work. This batch includes a total of 67 new specifications, among which 15 are injectables. The update aims to further standardize and improve the quality of generic drugs in the…
-
SciClone Pharmaceuticals Reports 10.8% Revenue Growth in 2022 Interim Results
•
SciClone Pharmaceuticals Inc., formerly a US-based and Nasdaq-listed company that became China-based after going private in 2017, has released its 2022 interim report. The company generated RMB 1.475 billion ($204.2 million) in revenues during the first half of this year, up 10.8% year-on-year (YOY). Operating profits grew by 8.4% YOY…
-
Harbour BioMed Doses First Subject in Phase I Study for HBM9378 in China
•
China-based Harbour BioMed (HKG: 2142) has announced the completion of the first subject dosing in a Phase I clinical study for HBM9378 (SKB378), a next-generation fully human antibody targeting thymic stromal lymphopoietin (TSLP), in patients with moderate-to-severe asthma. The study is being conducted in China and marks a significant step…
-
MicroPort CardioFlow’s Alwide Plus Balloon Catheter Approved in Colombia
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG: 0853), has announced that it has received marketing approval in Colombia for its in-house developed Alwide Plus balloon catheter. This marks another significant milestone in the global expansion of the company’s cardiovascular product portfolio. Product…
-
Zai Lab Licenses Seagen’s Tivdak for Greater China Development and Commercialization
•
Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has formed a collaboration with US-based biotech Seagen Inc. (Nasdaq: SGEN) to license development and commercialization rights in Greater China (including mainland China, Hong Kong, Taiwan, and Macau) to Tivdak (tisotumab vedotin). This strategic partnership aims to bring this innovative antibody-drug…
-
Telix Pharmaceuticals Gains IND Approval for TLX250-CDx in China
•
Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that it has received Investigational New Drug (IND) approval from China’s Center for Drug Evaluation (CDE). The company will now commence a pivotal Phase III registration study in China for its TLX250-CDx (89Zr-girentuximab), an imaging agent used to support positron emission tomography…
